Cardiovascular & Hematological Disorders-Drug Targets
Title:Acknowledgements to Reviewers
Volume: 17 Issue: 3
Author(s):
Affiliation:
Export Options
About this article
Cite this article as:
, Acknowledgements to Reviewers, Cardiovascular & Hematological Disorders-Drug Targets 2017; 17 (3) . https://dx.doi.org/10.2174/1871529X1703180209122053
DOI https://dx.doi.org/10.2174/1871529X1703180209122053 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
Related Journals
Related Books
24
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial : Full Blood Count and Peripheral Arterial Disease Severity and Prognosis
Current Vascular Pharmacology Development of Pin1 Inhibitors and their Potential as Therapeutic Agents
Current Medicinal Chemistry Fetal Asphyctic Preconditioning Protects Against Perinatal Asphyxia- Induced Apoptosis and Astrogliosis in Neonatal Brain
CNS & Neurological Disorders - Drug Targets Curcumin: A Potential Neuroprotective Agent in Parkinson's Disease
Current Pharmaceutical Design Foundation-Industry Relationships - A New Business Model Joint-Venture Philanthropy in Therapy Development
Current Topics in Medicinal Chemistry Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals Overproduction of 15N-Labeled r-RGD-Hirudin in Pichia pastoris for NMR Studies
Protein & Peptide Letters Statins and the Brain: More than Lipid Lowering Agents?
Current Neuropharmacology Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design Plasma Clusterin as a Potential Biomarker for Alzheimer’s Disease-A Systematic Review and Meta-analysis
Current Alzheimer Research Co-administration of Phycocyanobilin and/or Phase 2-Inducer Nutraceuticals for Prevention of Opiate Tolerance
Current Pharmaceutical Design Rho-Kinase and RGS-Containing RhoGEFs as Molecular Targets for the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Effect of Soy Isoflavone Supplementation on Endothelial Dysfunction and Oxidative Stress in Equol-Producing Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry Albumin Infusion Therapy in Stroke, Sepsis and the Critically Ill
Current Nutrition & Food Science Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Genome-Wide Association Studies: Is there a Genotype for Cognitive Decline in Older Persons with Type 2 Diabetes?
Current Pharmaceutical Design Neuroprotection by Methylene Blue in Cerebral Global Ischemic Injury Induced Blood-Brain Barrier Disruption and Brain Pathology: A Review
CNS & Neurological Disorders - Drug Targets A New Alzheimers Disease Interventive Strategy: GLP-1
Current Drug Targets Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets